Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc. experienced multiple planned and proposed sales by insiders, including the Chief Medical Officer and a director, throughout the first half of 2026. The most recent activity occurred on July 14, 2026. These transactions represent a consistent pattern of divestment rather than acquisition over the observed period.
Ticker: GALT Exchange: NAS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Galectin Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
95.02
Quantity 47,887 -33.9%
Value US$3,808,770
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
418.07
Quantity 19,874 -18.7%
Value US$4,014,068
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
126.79
Quantity 52,256 +23.5%
Value US$3,365,202
2.9
Harold Shlevin Director Non-Executive Director
Transaction date
Proposed sale
Price
5.04
Quantity 22,268
Value US$112,212
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
5.00
Quantity 7,732 -54.3%
Value US$38,660
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 2,533 -100.0%
Value US$12,665
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.00
Quantity 2,037 -100.0%
Value US$10,185
Jamil Khurram Officer Officer
Transaction date
Proposed sale
Price
5.00
Quantity 68,287
Value US$341,435
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
5.00
Quantity 7,732
Value US$38,680
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.14
Quantity 7,557 -100.0%
Value US$23,729
Jamil Khurram Officer Officer
Transaction date
Proposed sale
Price
3.14
Quantity 8,125
Value US$25,500
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.10
Quantity 568 -100.0%
Value US$1,761
4.1
ELDRED KARY Non-Executive Director
Transaction date
Purchase
Price
2.70
Quantity 300 +0.5%
Value US$810
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.65
Quantity 21,446 -100.0%
Value US$78,205
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
3.67
Quantity 20,354 -72.8%
Value US$74,695
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
3.58
Quantity 37,698 -4.3%
Value US$134,853
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.90
Quantity 25,499 -54.3%
Value US$99,408
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
3.90
Quantity 25,732 -47.9%
Value US$100,298
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
3.91
Quantity 27,731 -3.1%
Value US$108,342
2.9
Shlevin Harold H. Director Non-Executive Director
Transaction date
Proposed sale
Price
4.16
Quantity 441,500
Value US$1,836,640
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
4.20
Quantity 13,055 -21.8%
Value US$54,789
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
4.20
Quantity 13,914 -20.6%
Value US$58,394
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
4.20
Quantity 18,571 -2.0%
Value US$77,939
2.3
CALLICUTT JACK W Officer Officer
Transaction date
Proposed sale
Price
4.20
Quantity 60,000
Value US$252,000
2.3
LEWIS JOEL Officer Officer
Transaction date
Proposed sale
Price
4.20
Quantity 84,000
Value US$352,800
Jamil Khurram Officer Officer
Transaction date
Proposed sale
Price
4.20
Quantity 60,000
Value US$252,000
2.3
CALLICUTT JACK W Officer Officer
Transaction date
Proposed sale
Price
4.20
Quantity 141,206
Value US$593,065
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
4.07
Quantity 8,125 -100.0%
Value US$33,089
4.1
ELDRED KARY Non-Executive Director
Transaction date
Purchase
Price
3.73
Quantity 700 +1.1%
Value US$2,611
3.2
FREEMAN KEVIN D Non-Executive Director
Transaction date
Purchase
Price
3.55
Quantity 5,500 +11.1%
Value US$19,514
4.1
ELDRED KARY Non-Executive Director
Transaction date
Purchase
Price
3.73
Quantity 700 +1.1%
Value US$2,611
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
7.06
Quantity 7,829 -0.9%
Value US$55,241
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
7.04
Quantity 4,706 -42.0%
Value US$33,121
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
7.04
Quantity 19,793 -63.9%
Value US$139,303
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
7.04
Quantity 8,500 -100.0%
Value US$59,840
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
7.04
Quantity 6,463 -100.0%
Value US$45,500
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
7.04
Quantity 4,479 -100.0%
Value US$31,532
Jamil Khurram Officer Officer
Transaction date
Proposed sale
Price
7.04
Quantity 21,479
Value US$151,212
2.3
LEWIS JOEL Officer Officer
Transaction date
Proposed sale
Price
7.06
Quantity 40,000
Value US$282,244
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.97
Quantity 24,706
Value US$172,223
4.3
10X Fund, L.P. Large shareholder
Transaction date
Sale
Price
6.66
Quantity 30,681 -0.5%
Value US$204,335
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.30
Quantity 8,417 -42.9%
Value US$53,027
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.24
Quantity 8,417
Value US$52,542
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.27
Quantity 19,793 -63.9%
Value US$124,181
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.21
Quantity 19,793
Value US$122,993
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.21
Quantity 19,793
Value US$122,993
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.27
Quantity 16,790 -60.0%
Value US$105,206
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.21
Quantity 16,790
Value US$104,198
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.00
Quantity 20,000 -64.1%
Value US$120,040
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.02
Quantity 35,000 -75.7%
Value US$210,665
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
5.95
Quantity 25,000 -69.0%
Value US$148,650
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
5.96
Quantity 20,000 -64.1%
Value US$119,240
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
5.96
Quantity 20,000 -64.1%
Value US$119,240
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
5.95
Quantity 35,000 -75.7%
Value US$208,250
2.9
Shlevin Harold H. Non-Executive Director
Transaction date
Planned sale
Price
6.01
Quantity 4,000 -26.3%
Value US$24,020
2.9
HAROLD SHLEVIN DIRECTOR Non-Executive Director
Transaction date
Proposed sale
Price
6.02
Quantity 159,000
Value US$957,180
4.3
10X Fund, L.P. Large shareholder
Transaction date
Sale
Price
5.73
Quantity 120,000 -2.1%
Value US$687,600
4.3
10X Fund, L.P. Large shareholder
Transaction date
Sale
Price
5.47
Quantity 30,000 -0.5%
Value US$164,100
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.22
Quantity 18,210 -70.5%
Value US$113,321
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.22
Quantity 28,100 -78.7%
Value US$174,866
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
6.15
Quantity 6,783 -0.8%
Value US$41,723
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.03
Quantity 2,323 -23.4%
Value US$14,012
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.03
Quantity 19,701 -72.1%
Value US$118,831
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.03
Quantity 9,586 -55.7%
Value US$57,820
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
6.04
Quantity 15,680 -1.8%
Value US$94,643
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.47
Quantity 16,250 -78.4%
Value US$88,888
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.47
Quantity 41,500 -90.3%
Value US$227,005
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.47
Quantity 41,500 -90.3%
Value US$227,005
Jamil Khurram Chief Medical Officer Officer
Transaction date
Planned sale
Price
5.47
Quantity 21,867 -83.0%
Value US$119,612
Jamil Khurram Officer Officer
Transaction date
Proposed sale
Price
5.45
Quantity 121,117
Value US$660,088
4.3
10X Fund, L.P. Large shareholder
Transaction date
Sale
Price
5.25
Quantity 40,000 -0.7%
Value US$210,000
2.3
LEWIS JOEL President and CEO Executive Director
Transaction date
Planned sale
Price
6.03
Quantity 1,867 -0.2%
Value US$11,252
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.03
Quantity 1,736 -18.6%
Value US$10,468
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.03
Quantity 1,675 -18.0%
Value US$10,095
2.3
CALLICUTT JACK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
6.02
Quantity 1,880 -19.8%
Value US$11,321
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-07-16 2026-07-14 PlS Planned sale

Chief Medical Officer

Officer
47,887 -33.9%
95.02
US$3,808,770
47,887 -33.9% 95.02 US$3,808,770
2026-06-30 2026-06-29 PlS Planned sale Non-Executive Director
19,874 -18.7%
418.07
US$4,014,068
19,874 -18.7% 418.07 US$4,014,068
2026-06-30 2026-06-29 PlS Planned sale

Chief Medical Officer

Officer
52,256 +23.5%
126.79
US$3,365,202
52,256 +23.5% 126.79 US$3,365,202
2026-06-29 2026-06-29 PrS Proposed sale

Director

Non-Executive Director
22,268
5.04
US$112,212
22,268 5.04 US$112,212
2026-06-30 2026-06-26 PlS Planned sale Non-Executive Director
7,732 -54.3%
5.00
US$38,660
7,732 -54.3% 5.00 US$38,660
2026-06-30 2026-06-26 PlS Planned sale

Chief Medical Officer

Officer
2,533 -100.0%
5.00
US$12,665
2,533 -100.0% 5.00 US$12,665
2026-06-30 2026-06-26 PlS Planned sale

Chief Medical Officer

Officer
2,037 -100.0%
5.00
US$10,185
2,037 -100.0% 5.00 US$10,185
2026-06-26 2026-06-26 PrS Proposed sale

Officer

Officer
68,287
5.00
US$341,435
68,287 5.00 US$341,435
2026-06-26 2026-06-26 PrS Proposed sale

DIRECTOR

Non-Executive Director
7,732
5.00
US$38,680
7,732 5.00 US$38,680
2026-06-25 2026-06-23 PlS Planned sale

Chief Medical Officer

Officer
7,557 -100.0%
3.14
US$23,729
7,557 -100.0% 3.14 US$23,729
2026-06-23 2026-06-23 PrS Proposed sale

Officer

Officer
8,125
3.14
US$25,500
8,125 3.14 US$25,500
2026-05-28 2026-05-26 PlS Planned sale

Chief Medical Officer

Officer
568 -100.0%
3.10
US$1,761
568 -100.0% 3.10 US$1,761
2026-02-09 2026-02-06 B Purchase Non-Executive Director
300 +0.5%
2.70
US$810
300 +0.5% 2.70 US$810
2026-01-06 2026-01-06 PlS Planned sale

Chief Medical Officer

Officer
21,446 -100.0%
3.65
US$78,205
21,446 -100.0% 3.65 US$78,205
2026-01-06 2026-01-06 PlS Planned sale

Chief Financial Officer

Officer
20,354 -72.8%
3.67
US$74,695
20,354 -72.8% 3.67 US$74,695
2026-01-06 2026-01-06 PlS Planned sale

President and CEO

Executive Director
37,698 -4.3%
3.58
US$134,853
37,698 -4.3% 3.58 US$134,853
2026-01-06 2026-01-05 PlS Planned sale

Chief Medical Officer

Officer
25,499 -54.3%
3.90
US$99,408
25,499 -54.3% 3.90 US$99,408
2026-01-06 2026-01-05 PlS Planned sale

Chief Financial Officer

Officer
25,732 -47.9%
3.90
US$100,298
25,732 -47.9% 3.90 US$100,298
2026-01-06 2026-01-05 PlS Planned sale

President and CEO

Executive Director
27,731 -3.1%
3.91
US$108,342
27,731 -3.1% 3.91 US$108,342
2026-01-06 2026-01-02 PrS Proposed sale

Director

Non-Executive Director
441,500
4.16
US$1,836,640
441,500 4.16 US$1,836,640
2026-01-06 2026-01-02 PlS Planned sale

Chief Medical Officer

Officer
13,055 -21.8%
4.20
US$54,789
13,055 -21.8% 4.20 US$54,789
2026-01-06 2026-01-02 PlS Planned sale

Chief Financial Officer

Officer
13,914 -20.6%
4.20
US$58,394
13,914 -20.6% 4.20 US$58,394
2026-01-06 2026-01-02 PlS Planned sale

President and CEO

Executive Director
18,571 -2.0%
4.20
US$77,939
18,571 -2.0% 4.20 US$77,939
2026-01-05 2026-01-02 PrS Proposed sale

Officer

Officer
60,000
4.20
US$252,000
60,000 4.20 US$252,000
2026-01-02 2026-01-02 PrS Proposed sale

Officer

Officer
84,000
4.20
US$352,800
84,000 4.20 US$352,800
2026-01-02 2026-01-02 PrS Proposed sale

Officer

Officer
60,000
4.20
US$252,000
60,000 4.20 US$252,000
2026-01-02 2026-01-02 PrS Proposed sale

Officer

Officer
141,206
4.20
US$593,065
141,206 4.20 US$593,065
2026-01-05 2025-12-31 PlS Planned sale

Chief Medical Officer

Officer
8,125 -100.0%
4.07
US$33,089
8,125 -100.0% 4.07 US$33,089
2025-12-23 2025-12-23 B Purchase Non-Executive Director
700 +1.1%
3.73
US$2,611
700 +1.1% 3.73 US$2,611
2025-12-23 2025-12-23 B Purchase Non-Executive Director
5,500 +11.1%
3.55
US$19,514
5,500 +11.1% 3.55 US$19,514
2025-12-23 2025-12-23 B Purchase Non-Executive Director
700 +1.1%
3.73
US$2,611
700 +1.1% 3.73 US$2,611
2025-12-19 2025-12-17 PlS Planned sale

President and CEO

Executive Director
7,829 -0.9%
7.06
US$55,241
7,829 -0.9% 7.06 US$55,241
2025-12-19 2025-12-17 PlS Planned sale Non-Executive Director
4,706 -42.0%
7.04
US$33,121
4,706 -42.0% 7.04 US$33,121
2025-12-19 2025-12-17 PlS Planned sale Non-Executive Director
19,793 -63.9%
7.04
US$139,303
19,793 -63.9% 7.04 US$139,303
2025-12-19 2025-12-17 PlS Planned sale

Chief Medical Officer

Officer
8,500 -100.0%
7.04
US$59,840
8,500 -100.0% 7.04 US$59,840
2025-12-19 2025-12-17 PlS Planned sale

Chief Medical Officer

Officer
6,463 -100.0%
7.04
US$45,500
6,463 -100.0% 7.04 US$45,500
2025-12-19 2025-12-17 PlS Planned sale

Chief Medical Officer

Officer
4,479 -100.0%
7.04
US$31,532
4,479 -100.0% 7.04 US$31,532
2025-12-17 2025-12-17 PrS Proposed sale

Officer

Officer
21,479
7.04
US$151,212
21,479 7.04 US$151,212
2025-12-17 2025-12-17 PrS Proposed sale

Officer

Officer
40,000
7.06
US$282,244
40,000 7.06 US$282,244
2025-12-17 2025-12-17 PrS Proposed sale

DIRECTOR

Non-Executive Director
24,706
6.97
US$172,223
24,706 6.97 US$172,223
2025-12-18 2025-12-16 S Sale Large shareholder
30,681 -0.5%
6.66
US$204,335
30,681 -0.5% 6.66 US$204,335
2025-12-16 2025-12-15 PlS Planned sale Non-Executive Director
8,417 -42.9%
6.30
US$53,027
8,417 -42.9% 6.30 US$53,027
2025-12-15 2025-12-15 PrS Proposed sale

DIRECTOR

Non-Executive Director
8,417
6.24
US$52,542
8,417 6.24 US$52,542
2025-12-16 2025-12-12 PlS Planned sale Non-Executive Director
19,793 -63.9%
6.27
US$124,181
19,793 -63.9% 6.27 US$124,181
2025-12-15 2025-12-12 PrS Proposed sale

DIRECTOR

Non-Executive Director
19,793
6.21
US$122,993
19,793 6.21 US$122,993
2025-12-12 2025-12-12 PrS Proposed sale

DIRECTOR

Non-Executive Director
19,793
6.21
US$122,993
19,793 6.21 US$122,993
2025-12-10 2025-12-09 PlS Planned sale Non-Executive Director
16,790 -60.0%
6.27
US$105,206
16,790 -60.0% 6.27 US$105,206
2025-12-09 2025-12-09 PrS Proposed sale

DIRECTOR

Non-Executive Director
16,790
6.21
US$104,198
16,790 6.21 US$104,198
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
20,000 -64.1%
6.00
US$120,040
20,000 -64.1% 6.00 US$120,040
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
35,000 -75.7%
6.02
US$210,665
35,000 -75.7% 6.02 US$210,665
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
25,000 -69.0%
5.95
US$148,650
25,000 -69.0% 5.95 US$148,650
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
20,000 -64.1%
5.96
US$119,240
20,000 -64.1% 5.96 US$119,240
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
20,000 -64.1%
5.96
US$119,240
20,000 -64.1% 5.96 US$119,240
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
35,000 -75.7%
5.95
US$208,250
35,000 -75.7% 5.95 US$208,250
2025-12-10 2025-12-08 PlS Planned sale Non-Executive Director
4,000 -26.3%
6.01
US$24,020
4,000 -26.3% 6.01 US$24,020
2025-12-08 2025-12-08 PrS Proposed sale

DIRECTOR

Non-Executive Director
159,000
6.02
US$957,180
159,000 6.02 US$957,180
2025-12-04 2025-12-03 S Sale Large shareholder
120,000 -2.1%
5.73
US$687,600
120,000 -2.1% 5.73 US$687,600
2025-12-04 2025-12-02 S Sale Large shareholder
30,000 -0.5%
5.47
US$164,100
30,000 -0.5% 5.47 US$164,100
2025-11-19 2025-11-18 PlS Planned sale

Chief Financial Officer

Officer
18,210 -70.5%
6.22
US$113,321
18,210 -70.5% 6.22 US$113,321
2025-11-19 2025-11-18 PlS Planned sale

Chief Financial Officer

Officer
28,100 -78.7%
6.22
US$174,866
28,100 -78.7% 6.22 US$174,866
2025-11-19 2025-11-18 PlS Planned sale

President and CEO

Executive Director
6,783 -0.8%
6.15
US$41,723
6,783 -0.8% 6.15 US$41,723
2025-11-19 2025-11-17 PlS Planned sale

Chief Financial Officer

Officer
2,323 -23.4%
6.03
US$14,012
2,323 -23.4% 6.03 US$14,012
2025-11-19 2025-11-17 PlS Planned sale

Chief Financial Officer

Officer
19,701 -72.1%
6.03
US$118,831
19,701 -72.1% 6.03 US$118,831
2025-11-19 2025-11-17 PlS Planned sale

Chief Financial Officer

Officer
9,586 -55.7%
6.03
US$57,820
9,586 -55.7% 6.03 US$57,820
2025-11-19 2025-11-17 PlS Planned sale

President and CEO

Executive Director
15,680 -1.8%
6.04
US$94,643
15,680 -1.8% 6.04 US$94,643
2025-11-14 2025-11-13 PlS Planned sale

Chief Medical Officer

Officer
16,250 -78.4%
5.47
US$88,888
16,250 -78.4% 5.47 US$88,888
2025-11-14 2025-11-13 PlS Planned sale

Chief Medical Officer

Officer
41,500 -90.3%
5.47
US$227,005
41,500 -90.3% 5.47 US$227,005
2025-11-14 2025-11-13 PlS Planned sale

Chief Medical Officer

Officer
41,500 -90.3%
5.47
US$227,005
41,500 -90.3% 5.47 US$227,005
2025-11-14 2025-11-13 PlS Planned sale

Chief Medical Officer

Officer
21,867 -83.0%
5.47
US$119,612
21,867 -83.0% 5.47 US$119,612
2025-11-13 2025-11-13 PrS Proposed sale

Officer

Officer
121,117
5.45
US$660,088
121,117 5.45 US$660,088
2025-11-12 2025-11-11 S Sale Large shareholder
40,000 -0.7%
5.25
US$210,000
40,000 -0.7% 5.25 US$210,000
2025-11-12 2025-11-10 PlS Planned sale

President and CEO

Executive Director
1,867 -0.2%
6.03
US$11,252
1,867 -0.2% 6.03 US$11,252
2025-11-12 2025-11-10 PlS Planned sale

Chief Financial Officer

Officer
1,736 -18.6%
6.03
US$10,468
1,736 -18.6% 6.03 US$10,468
2025-11-12 2025-11-10 PlS Planned sale

Chief Financial Officer

Officer
1,675 -18.0%
6.03
US$10,095
1,675 -18.0% 6.03 US$10,095
2025-11-12 2025-11-10 PlS Planned sale

Chief Financial Officer

Officer
1,880 -19.8%
6.02
US$11,321
1,880 -19.8% 6.02 US$11,321

See older Galectin Therapeutics Inc insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Galectin Therapeutics Inc history with Plus

Billed monthly · Cancel anytime